DaVita (NYSE:DVA) Issues Quarterly Earnings Results, Beats Estimates By $0.43 EPS

DaVita (NYSE:DVA) posted its earnings results on Thursday. The company reported $2.38 EPS for the quarter, topping analysts’ consensus estimates of $1.95 by $0.43, RTT News reports. The business had revenue of $3.07 billion during the quarter, compared to analyst estimates of $3.03 billion. DaVita had a return on equity of 66.59% and a net margin of 6.61%. The company’s quarterly revenue was up 6.9% compared to the same quarter last year. During the same quarter last year, the company earned $1.58 EPS. DaVita updated its FY24 guidance to $9.00-$9.80 EPS.

DaVita Trading Down 5.5 %

Shares of DVA stock opened at $134.45 on Friday. The company has a debt-to-equity ratio of 6.65, a current ratio of 1.19 and a quick ratio of 1.13. The company has a market cap of $11.79 billion, a price-to-earnings ratio of 15.28, a PEG ratio of 1.20 and a beta of 1.04. DaVita has a 1 year low of $71.51 and a 1 year high of $145.04. The firm has a fifty day moving average price of $133.71 and a 200-day moving average price of $112.84.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the company. Truist Financial boosted their target price on DaVita from $130.00 to $135.00 and gave the stock a “hold” rating in a research report on Tuesday, February 20th. Barclays began coverage on shares of DaVita in a report on Wednesday, March 6th. They issued an “equal weight” rating and a $133.00 target price on the stock. TheStreet raised shares of DaVita from a “c+” rating to a “b-” rating in a research report on Wednesday, February 7th. UBS Group increased their price target on DaVita from $113.00 to $134.00 and gave the company a “buy” rating in a report on Wednesday, February 14th. Finally, StockNews.com raised DaVita from a “buy” rating to a “strong-buy” rating in a report on Thursday, April 25th. Two analysts have rated the stock with a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, DaVita presently has a consensus rating of “Moderate Buy” and an average price target of $118.50.

Insider Buying and Selling

In other DaVita news, insider James O. Hearty sold 26,164 shares of the business’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $119.64, for a total transaction of $3,130,260.96. Following the completion of the sale, the insider now owns 20,264 shares of the company’s stock, valued at $2,424,384.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other DaVita news, insider James O. Hearty sold 26,164 shares of the firm’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $119.64, for a total transaction of $3,130,260.96. Following the sale, the insider now owns 20,264 shares in the company, valued at approximately $2,424,384.96. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Javier Rodriguez sold 67,603 shares of the company’s stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $126.11, for a total transaction of $8,525,414.33. Following the completion of the transaction, the chief executive officer now owns 488,697 shares of the company’s stock, valued at $61,629,578.67. The disclosure for this sale can be found here. In the last three months, insiders have sold 134,540 shares of company stock valued at $16,551,071. 1.40% of the stock is owned by company insiders.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.